Gufic Biosciences Key Ratios
NSE: GUFICBIO | BSE: 509079
₹412.20
As on 27-Aug-2026IST
Market cap
₹4,122 Cr
Revenue (TTM)
₹981 Cr
P/E Ratio
56.1
P/B Ratio
6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 3.48 | 14.94 | 15.46 | 10.59 | 7.53 |
| EBIT | 1.99 | 58.53 | 25.09 | 5.46 | 4.14 |
| Net Profit | 9.16 | 86.06 | 20.26 | -2.47 | -0.88 |
| EPS | 9.16 | 86.06 | 20.26 | -3.57 | -1.55 |
| Book Value | -- | -- | 10.46 | 22.67 | 29.92 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| -- | 15.15 | 13.64 | 12.77 | 14.03 |
| Net Margin
| -- | 9.92 | 7.47 | 6.78 | 8.46 |
| Return on equity
| -- | 22.21 | 11.33 | 10.14 | 12.29 |
| Return on Capital
| -- | 22.81 | -- | 12.56 | 13.48 |
| Return on Assets
| -- | 10.39 | 5.85 | 5.11 | 6.16 |
| Debt to Equity (x)
| -- | -- | 0.16 | 0.58 | 0.52 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
--
|
12.56
|
13.48
|
15.59
|
--
|
|
Peer Median
|
--
|
19.34
|
21.76
|
21.89
|
--
|
ROE
11.33
Lower than Peers by 4.01
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
11.33
|
10.14
|
12.29
|
16.17
|
--
|
|
Peer Median
|
15.35
|
16.97
|
17.93
|
16.42
|
--
|
ROA
5.85
Lower than Peers by 4.50
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
5.85
|
5.11
|
6.16
|
7.88
|
--
|
|
Peer Median
|
10.35
|
9.88
|
12.81
|
12.32
|
--
|
EBIT Margin
13.64
Lower than Peers by 4.37
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
13.64
|
12.77
|
14.03
|
16.15
|
--
|
|
Peer Median
|
18.01
|
18.96
|
18.93
|
21.05
|
--
|
Net Margin
7.47
Lower than Peers by 6.98
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
7.47
|
6.78
|
8.46
|
10.65
|
--
|
|
Peer Median
|
14.45
|
13.29
|
14.94
|
15.51
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
--
|
7.78
|
8.24
|
10.97
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
16.70
Higher than Peers by 4.75
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
16.70
|
15.15
|
1.63
|
--
|
--
|
|
Peer Median
|
11.95
|
12.97
|
10.90
|
13.44
|
--
|
EBIT Growth
24.21
Higher than Peers by 2.61
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
24.21
|
4.75
|
-11.70
|
--
|
--
|
|
Peer Median
|
21.60
|
15.05
|
15.01
|
23.50
|
--
|
Net Profit Growth
20.26
Lower than Peers by 2.48
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
20.26
|
-7.81
|
-19.14
|
--
|
--
|
|
Peer Median
|
22.73
|
11.89
|
14.80
|
30.12
|
--
|
EPS Growth
20.26
Higher than Peers by 0.23
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
20.26
|
-7.81
|
-19.14
|
--
|
--
|
|
Peer Median
|
20.03
|
12.16
|
14.27
|
29.02
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
--
|
10.65
|
12.85
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.16
Higher than Peers by 0.15
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
0.16
|
0.58
|
0.52
|
0.60
|
--
|
|
Peer Median
|
0.00
|
0.05
|
0.06
|
0.03
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
--
|
0.38
|
0.26
|
0.27
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.55
Lower than Peers by 0.53
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
1.55
|
1.55
|
1.61
|
1.61
|
--
|
|
Peer Median
|
2.08
|
1.93
|
1.90
|
2.23
|
--
|
Quick Ratio
0.92
Lower than Peers by 0.61
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
0.92
|
0.92
|
1.05
|
1.08
|
--
|
|
Peer Median
|
1.54
|
1.52
|
1.46
|
1.59
|
--
|
Interest Coverage
3.71
Lower than Peers by 15.67
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
3.71
|
3.36
|
4.84
|
7.89
|
--
|
|
Peer Median
|
19.38
|
19.95
|
24.96
|
45.29
|
--
|
Operating Efficiency
Debtors to sales
30.31
Higher than Peers by 8.93
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
30.31
|
31.50
|
38.38
|
40.90
|
--
|
|
Peer Median
|
21.38
|
19.87
|
21.77
|
20.10
|
--
|
Asset Turnover
0.78
Higher than Peers by 0.06
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
0.78
|
0.97
|
0.97
|
0.86
|
--
|
|
Peer Median
|
0.72
|
0.77
|
0.76
|
0.81
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
--
|
91.39
|
106.89
|
128.09
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
--
|
80.84
|
69.22
|
77.83
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
--
|
187.06
|
191.37
|
178.99
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
--
|
-14.82
|
-15.25
|
26.94
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
56.11
Higher than Peers by 22.35
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
56.11
|
42.88
|
48.44
|
32.96
|
--
|
|
Peer Median
|
33.76
|
34.32
|
26.81
|
39.85
|
--
|
Price / Book Value
6.00
Higher than Peers by 1.08
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
6.00
|
4.14
|
5.61
|
5.33
|
--
|
|
Peer Median
|
4.92
|
5.12
|
4.65
|
6.11
|
--
|
Dividend Yield
0.02
Lower than Peers by 0.48
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
0.02
|
0.04
|
0.03
|
0.04
|
--
|
|
Peer Median
|
0.50
|
0.51
|
0.61
|
0.37
|
--
|
EV/EBITDA
26.56
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
26.56
|
19.89
|
26.16
|
21.03
|
--
|
|
Peer Median
|
--
|
30.38
|
27.02
|
34.57
|
--
|
Market Cap
4,122
Lower than Peers by 15,026
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Gufic Biosciences
|
4,122
|
2,753
|
3,374
|
2,839
|
--
|
|
Peer Median
|
19,147
|
18,013
|
20,914
|
25,297
|
--
|